PD-L1 antibody

Catalog No. ABIN7608014

The Human Chimeric anti-PD-L1 antibody has been validated for WB. It is suitable to detect PD-L1 in samples from Human.

Quick Overview for PD-L1 antibody (ABIN7608014)

Target: PD-L1 (CD274 (PD-L1))

Reactivity: Human

Host: Human, Rabbit

Clonality: Chimeric

Conjugate: This PD-L1 antibody is un-conjugated

Application: Western Blotting (WB)

Clone: 23D8

Product Details anti-PD-L1 Antibody

Purpose: Anti-PDL1 antibody(23D8), IgG1 Chimeric mAb

Purification: Purified from cell culture supernatant by affinity chromatography

Isotype: IgG1

Application Details

Application Notes: WB 1:1000

Restrictions: For Research Use only

Handling

Format: Lyophilized

Buffer: Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8 % trehalose is added as protectants before lyophilization.

Storage: -20 °C,-80 °C

Storage Comment: Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.

Expiry Date: 12 months

Target Details for PD-L1

Target: PD-L1 (CD274 (PD-L1))

Alternative Name: PDL1

Background: This gene encodes an immune inhibitory receptor ligand that is expressed by hematopoietic and non-hematopoietic cells, such as T cells and B cells and various types of tumor cells. The encoded protein is a type I transmembrane protein that has immunoglobulin V-like and C-like domains. Interaction of this ligand with its receptor inhibits T-cell activation and cytokine production. During infection or inflammation of normal tissue, this interaction is important for preventing autoimmunity by maintaining homeostasis of the immune response. In tumor microenvironments, this interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human malignancies, including colon cancer and renal cell carcinoma. Alternative splicing results in multiple transcript variants.

UniProt: Q9NZQ7

Pathways: Cancer Immune Checkpoints